

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL
For FY 2006☐ Applicant claims small entity status. See 37 CFR 1.27TOTAL AMOUNT OF PAYMENT (\$)
180.00**Complete if Known**

Application Number	10/735,577
Filing Date	December 12, 2003
First Named Inventor	David Waisman
Examiner Name	Tracy A. Vivlemore
Art Unit	1632
Attorney Docket No.	101982

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____☒ Deposit Account Deposit Account Number: 50-1662 Deposit Account Name: Polsinelli Shalton Welte Suelthaus

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION (All the fees below are due upon filing or may be subject to a surcharge.)**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee (\$)	Small Entity Fee (\$)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180
Total Claims	Extra Claims	Fee (\$)
- 20 or HP = _____ x _____ = _____		
HP = highest number of total claims paid for, if greater than 20.		
Indep. Claims	Extra Claims	Fee (\$)
- 3 or HP = _____ x _____ = _____		
HP = highest number of independent claims paid for, if greater than 3.		

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 = _____	/ 50 = _____	(round up to a whole number) x _____	= _____	

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)


Other (e.g., late filing surcharge): Submission of First Supplemental Information Disclosure Statement 180.00**SUBMITTED BY**

Signature		Registration No. (Attorney/Agent) 40,593	Telephone 314-889-8000
Name (Print/Type)	Kathryn J. Doty		Date May 10, 2006

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)			Matter No.
Applicants: David Waisman			101982
Serial No.	Filing Date	Examiner	Group Art Unit
10/735,577	December 12, 2003	Tracy A. Vivlemore	1632
Invention: COMPOSITIONS AND METHODS FOR INHIBITING TUMOR GROWTH AND METASTASIS			
<p>I hereby certify that:</p> <ul style="list-style-type: none"><input checked="" type="checkbox"/> Letter to the Commissioner for Patents (1 page);<input checked="" type="checkbox"/> First Supplemental Information Disclosure Statement by Application form PTO/SB08A (1 page);<input checked="" type="checkbox"/> Eleven (11) Non Patent Literature Documents;<input checked="" type="checkbox"/> Fee Transmittal Sheet (1 page in duplicate);<input checked="" type="checkbox"/> A Certificate of Mailing By "Express Mail" (1 page);<input checked="" type="checkbox"/> Authorization to charge any and all fees, which may be required, or credit any overpayment to Deposit Account No. 50-1662; and<input checked="" type="checkbox"/> A stamped, pre-addressed postcard are being mailed by U.S. Postal Service Express Mail to: Mail Stop – Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, this 10th day of May 2006. <div style="text-align: right;"><p><u>Karen Jaeger</u> (Typed or Printed Name of Person Mailing Correspondence)</p><p><u></u> (Signature of Person Mailing Correspondence)</p><p><u>EV 535074444 US</u> (“Express Mail” Mailing Label Number)</p></div>			



5-11-06

IFW \$
PATENT

Atty. Docket No. 101982
Express Mail Label EV 535074444 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): David Waisman Art Unit 1632
Serial No.: 10/735,577 Examiner: Tracy A. Vivlemore
Filed: December 12, 2003 Conf. No. 2576
For: COMPOSITIONS AND METHODS FOR INHIBITING TUMOR GROWTH
AND METASTASIS

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, Applicants submit the attached PTO/SB/08A form and copies of eleven (11) non patent literature documents, for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 50-1662.

Respectfully submitted,


POLSINELLI SHALTON WELTE SUELTHAUS PC

Date: May 10, 2006

Kathryn J. Doty, Reg. No. 40,593
100 South Fourth Street, Suite 1100
St. Louis, Missouri 63102
Tel: (314) 889-8000
Fax: (314) 231-1776
Attorney for Applicants

05/15/2006 RMEBRAFT 00000094 501662 10735577

01 FC:1806 180.00 DA



PTO/SB08A (07-05

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paper Work Reduction Act of 1995, no person are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**FIRST SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICATION**
(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/735,577
Filing Date	12/12/2003
First Named Inventor	David Waisman
Art Unit	1632
Examiner Name	Tracy A. Vivlemore
Attorney Docket Number	101982

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U	4,462,980	07/31/1984	Diedrichsen et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
--------------------	-----------------------	--	--------------------------------	--	--	----------------

Examiner Signature	Date Considered
--------------------	-----------------

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the authority (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	V	BALLAGAMBA et al, "Tyrosine phosphorylation of annexin II tetramer is stimulated by membrane binding." J Biol Chem., 1997, Vol. 272, No. 6, pp. 3195-9.	
	W	BROOKS et al., "Ca2+-dependent and phospholipid-independent binding of annexin 2 and annexin 5." Biochem J., 2002, Vol. 367, Pt 3, pp. 895-900.	
	X	CAO et al., "Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells." J Biol Chem., 1996, Vol. 271, No. 46, pp. 29461-7.	
	Y	FALCONE et al., "Macrophage formation of angiostatin during inflammation. A byproduct of the activation of plasminogen." J Biol Chem., 1998, Vol. 273, No. 47, pp 31480-5.	
	Z	GATELY et al., "The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin." Proc Natl Acad Sci U S A, 1997, Vol. 94, No. 20, pp 10868-72.	
	AA	JOHNSSON et al., "Alkylation of cysteine 82 of p11 abolishes the complex formation with the tyrosine-protein kinase substrate p36 (annexin 2, calpactin 1, lipocortin 2)." J Biol Chem., 1990, Vol. 265, No. 24, pp. 14464-8.	
	AB	KASSAM et al. "Characterization of the heparin binding properties of annexin II tetramer." J Biol Chem., 1997, Vol. 272, No. 24, pp. 15093-100.	
	AC	KWON et al., "p22 is a novel plasminogen fragment with antiangiogenic activity." Biochemistry, 2001, Vol. 40, No. 44, pp. 13246-53.	
	AD	Soff, "Angiostatin and angiostatin-related proteins." Cancer Metastasis Rev., 2000, Vol. 19, No. (1-2), pp. 97-107.	
	AE	STATHAKIS et al., "Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin." J Biol Chem., 1999, Vol. 274, No. 13, pp. 8910-6.	
	AF	TERATANI et al., "Induced transcriptional expression of calcium-binding protein S100A1 and S100A10 genes in human renal cell carcinoma." Cancer Lett., 2002, Vol. 175, No. 1, pp. 71-7.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. patent and Trademark Office, PO Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.